Do BHMT rs3733890 AG and PEMT rs7946 CT reduce choline- and betaine-dependent homocysteine buffering?

Cellular homocysteine clearance is maintained through a delicate balance between parallel remethylation pathways. When genetic variations compromise auxiliary pathways, systemic metabolic reliance shifts dramatically to primary nutrient-dependent mechanisms.

Mechanistic shift in remethylation

• Dual-pathway clearance: Homocysteine is cleared via the primary folate- and vitamin B12-dependent methionine synthase (MTR) pathway, or the alternative, B12-independent betaine-homocysteine S-methyltransferase (BHMT) pathway. The BHMT pathway utilizes betaine, oxidized from dietary choline, to perform up to 50% of hepatic homocysteine remethylation.
• Enzymatic impairment: The BHMT rs3733890 (R239Q) coding variant reduces the efficiency of betaine-dependent remethylation, while the PEMT rs7946 variant impairs endogenous phosphatidylcholine synthesis. This reduction in phosphatidylcholine depletes the downstream choline and betaine pools essential for BHMT activity.
• Compensatory load shifting: Restricting the alternate BHMT pathway forces a compensatory shift in metabolic flux, funneling excess homocysteine directly into the remaining MTR pathway and placing an absolute demand on available folate and vitamin B12 cofactors.

Clinical and dietary implications

• Nutritional vulnerability: While these heterozygous variants do not independently cause severe hyperhomocysteinemia under normal conditions, they severely compromise the body's backup buffering capacity.
• Elevated risk markers: Under dietary folate restriction, individuals carrying the PEMT rs7946 risk allele demonstrate significantly larger increases in plasma homocysteine. Similarly, carriers of the BHMT rs3733890 mutant allele show susceptibility to folate therapy failure when dietary choline or betaine is deficient.
• Model evidence: Genetic knockout models of BHMT deficiency confirm that losing this alternative pathway triggers severe hyperhomocysteinemia, shifting the functional burden of homocysteine regulation entirely onto B-vitamin status.

Bottom line

• The BHMT rs3733890 and PEMT rs7946 variants collectively reduce the auxiliary choline- and betaine-dependent buffering capacity for homocysteine remethylation, shifting the metabolic burden of clearance onto the primary MTR pathway and making the individual highly dependent on optimal folate and vitamin B12 status to prevent hyperhomocysteinemia.